Latest Reproductive Health News

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

EVE Health Group has appointed Dr Fiona Cousins as the inaugural member of its Scientific Advisory Board, reinforcing its commitment to advancing treatments for dysmenorrhoea and endometriosis ahead of the commercial launch of Dyspro™.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.